AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06108063
Drug: Placebo - Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
Trial: NCT00038259
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04951648
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Trial: NCT06692491
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Albumin-Bound Paclitaxel 260mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with albumin-bound paclitaxel if PDOs show the highest response to this drug under the guidance of MTB.
Trial: NCT06692491
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with epirubicin if PDOs show the highest response to this drug under the guidance of MTB.
Trial: NCT06692491
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with gemcitabine if PDOs show the highest response to this drug under the guidance of MTB.
Trial: NCT06692491
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25-30mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with vinorelbine if PDOs show the highest response to this drug under the guidance of MTB.
Trial: NCT06692491
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with cisplatin if PDOs show the highest response to this drug under the guidance of MTB.
Trial: NCT06692491
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 125mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with irinotecan if PDOs show the highest response to this drug under the guidance of MTB.
Trial: NCT06692491
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with nivolumab under the guidance of MTB.
Trial: NCT06692491
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with pembrolizumab under the guidance of MTB.
Trial: NCT06692491
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 10mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with durvalumab under the guidance of MTB.
Trial: NCT06692491
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with atezolizumab under the guidance of MTB.
Trial: NCT06692491
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with sintilimab under the guidance of MTB.
Trial: NCT06692491
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with tislelizumab under the guidance of MTB.
Trial: NCT06692491
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with camrelizumab under the guidance of MTB.
Trial: NCT06692491
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with toripalimab under the guidance of MTB.
Trial: NCT06692491
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with serplulimab under the guidance of MTB.
Trial: NCT06692491
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab 20mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with adebrelimab under the guidance of MTB.
Trial: NCT06692491
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envafolimab 150mg,qw Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with envafolimab under the guidance of MTB.
Trial: NCT06692491
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib 80mg,qd Patients with advanced rare tumours who failed to standard treatment carrying EGFR mutations will be administrated with osimertinib under the guidance of MTB.
Trial: NCT06692491
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alectinib 600mg,bid Patients with advanced rare tumours who failed to standard treatment carrying ALK fusion will be administrated with alectinib under the guidance of MTB.
Trial: NCT06692491
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRAF V600E mutation will be administrated with vemurafenib under the guidance of MTB.
Trial: NCT06692491
Drug: Pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib 60mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRCA1/2 mutation will be administrated with pamiparib under the guidance of MTB.
Trial: NCT06692491
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib under the guidance of MTB.
Trial: NCT06692491
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying CKIT mutation will be administrated with imatinib under the guidance of MTB.
Trial: NCT06692491
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib 125mg, 21/7 dosing schedule Patients with advanced rare tumours who failed to standard treatment following HR(+)/HER-2(-) will be administrated with palbociclib under the guidance of MTB.
Trial: NCT06692491
Drug: Savolitinib
RxNorm normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib 300mg, qd Patients with advanced rare tumours who failed to standard treatment carrying C-MET mutation will be administrated with savolitinib under the guidance of MTB.
Trial: NCT06692491
Drug: Entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Entrectinib 600mg, qd Patients with advanced rare tumours who failed to standard treatment carrying ROS-1 fusion or NTRK fusion will be administrated with entrectinib under the guidance of MTB.
Trial: NCT06693440
Drug: PD-1 Inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
Trial: NCT05701436
Drug: Lobaplatin
RxNorm normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Trial: NCT05701436
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg per square body surface area was used for monthly transhepatic arterial infusions.
Trial: NCT05701436
Drug: Lobaplatin, Raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Trial: NCT04429308
Drug: Chemical Peels
RxNorm normalized name: orange peel extract
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured Ethyl Alcohol AND 35% Trichloroacetic acid peels
Trial: NCT04558918
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion
Trial: NCT04558918
Drug: Ravulizumab
RxNorm normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion
Trial: NCT06692010
Drug: Bupivacaine with Dexamethasone Solution
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 to 15 ml %0.25 bupivacaine \& 4 mg Dexamethazone
Trial: NCT06517953
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An orally first-generation EGFR inhibitior.
Trial: NCT06517953
Drug: Befotertinib
RxNorm normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
Trial: NCT05239286
Drug: Conventional fluid managment
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer solution at the dose of 5 ml/kg/h infused throughout the surgical procedure by taking the parameters such as Heart rate (HR), mean arterial pressure (MAP) and urine output, Hypotension was defined as a condition in which the MAP was below 30% of the baseline MAP of the patient. In this case, bolus of 250 ml crystalloids (0.9% NaCl) was given and in case of hypotension persistence, 5 mg I.V. ephedrine administered and repeated every 5 min till the MAP increased over 70% of baseline.
Trial: NCT06194201
Drug: Caspofungin Acetate for Injection
RxNorm normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing frequency: D1 70mg，followed by 50mg intravenously once daily
Trial: NCT06467435
Drug: Kamuvudine-9
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 96 mg tablets taken twice a day for 4 weeks
Trial: NCT06467435
Drug: Kamuvudine-9
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 96 mg tablets taken once
Trial: NCT05520619
Drug: Paclitaxel, Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.
Trial: NCT05520619
Drug: tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
Trial: NCT05571943
Drug: Difamilast
RxNorm normalized name: Difamilast
DrugBank: Difamilast (DB14987)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Difamilast Ointment 1%
Trial: NCT05934799
Drug: Clopidogrel film-coated tablet 75 mg
RxNorm normalized name: clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.
Trial: NCT02145910
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05293132
Drug: Montelukast Sodium 10 mg
RxNorm normalized name: MONTELUKAST SODIUM 10 mg ORAL TABLET
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film coated tablets containing 10 mg montelukast
Trial: NCT05293132
Drug: Co-Enzyme Q10
RxNorm normalized name: Thrifty White Co-Enzyme Q10 100mg Capsule
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules contain 210 mg Co-Enzyme Q10
Trial: NCT05293132
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
Trial: NCT05027646
Drug: Sancuso - Part 1
RxNorm normalized name: Sancuso
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
Trial: NCT05027646
Drug: Sancuso - Part 2
RxNorm normalized name: Sancuso
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
Trial: NCT05635734
Drug: Azeliragon 5 mg
RxNorm normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Trial: NCT05635734
Drug: Azeliragon 10 mg
RxNorm normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Trial: NCT05635734
Drug: Azeliragon 20 mg
RxNorm normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Trial: NCT05178953
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
Trial: NCT00000455
Drug: naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04860713
Drug: aspirin and ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
Trial: NCT04906889
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
Trial: NCT04906889
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
Trial: NCT04908449
Drug: Rectus sheath block with bupivacaine
RxNorm normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectus sheath block with local anesthetic versus sham block with saline
Trial: NCT05298033
Drug: Crisaborole 2 % Topical Ointment
RxNorm normalized name: crisaborole 2 % Topical Ointment
DrugBank: Crisaborole (DB05219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Twice daily crisaborole 2% topical ointment
Trial: NCT05298033
Drug: PF-07038124 0.01% topical ointment
DrugBank: PF-07038124 (DB19143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily PF-07038124 0.01% topical ointment
Trial: NCT06663358
Drug: Pegunigalsidase-alfa
RxNorm normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via intravenous (IV) infusion under conditions of routine clinical care
Trial: NCT05095857
Drug: S-ketamine
RxNorm normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
Trial: NCT00000849
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04714073
Drug: BI 706321
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 706321
Trial: NCT04714073
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole
Trial: NCT06535529
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
Trial: NCT06535529
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics